mitomycin has been researched along with Leukopenia in 66 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity." | 9.16 | Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer. ( Blohmer, JU; du Bois, A; Lück, HJ; Schippert, C; Warm, M, 2012) |
| "Following a reported 23% response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) + MAP + sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP + sargramostim in patients with advanced uterine leiomyosarcoma." | 9.11 | Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Long, HJ; Sorosky, J, 2005) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 9.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| " The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas." | 9.09 | Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 9.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 9.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "A randomized clinical trial was performed to determine if combination therapy with doxorubicin, vincristine, and mitomycin C (DVM) was superior to doxorubicin alone in women with metastatic breast cancer for whom prior chemotherapy had failed." | 9.06 | Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. ( Foley, JF; Gerstner, JB; Ingle, JN; Krook, JE; Long, HJ; Mailliard, JA; Marschke, RF; McCormack, GW; Pfeifle, DM; Schaid, DJ, 1989) |
| "During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)." | 7.85 | Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. ( Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 7.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied." | 7.67 | [Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985) |
| "The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary." | 7.67 | 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 7.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| "Mitomycin C together with either vindesine or vinblastine was given to 48 patients with previously treated advanced breast cancer." | 7.66 | Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. ( Brooks, RJ; Garewal, HS; Jones, SE; Miller, TP, 1983) |
| "Patients with metastatic breast cancer (MBC) with disease progression after anthracycline-and/or taxane-containing therapy need an effective drug regimen with low toxicity." | 5.16 | Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer. ( Blohmer, JU; du Bois, A; Lück, HJ; Schippert, C; Warm, M, 2012) |
| "Following a reported 23% response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) + MAP + sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP + sargramostim in patients with advanced uterine leiomyosarcoma." | 5.11 | Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Long, HJ; Sorosky, J, 2005) |
| "Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery." | 5.10 | Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002) |
| " The aim of the present study was to evaluate the effectiveness and safety of a combined-treatment modality consisting of systemic chemotherapy with 24-h continuous infusional gemcitabine and mitomycin C, plus external beam radiotherapy in patients with localized unresectable adenocarcinoma of the pancreas." | 5.09 | Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. ( Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H, 2001) |
| "We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
| "From December 1988 to February 1991, 112 consecutive patients were submitted to epirubicin + mitomycin C chemotherapy as first-line treatment for advanced breast cancer." | 5.07 | Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer. ( Algeri, R; Guarnieri, A; Neri, B; Pacini, P; Rinaldini, M; Tucci, E; Valzelli, S, 1994) |
| "One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomycin C (FAM) or sequential chemotherapy with the same agents, i." | 5.07 | Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. ( Hahn, RG; Krook, JE; Laurie, JA; Mailliard, JA; Morton, RF; Patel, SR; Therneau, TM; Twito, DI; Windschitl, HE, 1992) |
| "A randomized clinical trial was performed to determine if combination therapy with doxorubicin, vincristine, and mitomycin C (DVM) was superior to doxorubicin alone in women with metastatic breast cancer for whom prior chemotherapy had failed." | 5.06 | Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer. ( Foley, JF; Gerstner, JB; Ingle, JN; Krook, JE; Long, HJ; Mailliard, JA; Marschke, RF; McCormack, GW; Pfeifle, DM; Schaid, DJ, 1989) |
| "One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)." | 5.06 | A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990) |
| "Age, APACHE score at ICU admission, neurological disease, sepsis and duration of mechanical ventilation were all independent risk factors for the development of delirium in ICU patients." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Consecutive patients with locally advanced (T2 ≥ 4 cm-T4 or N+) anal cancer scheduled for two cycles of concomitant 5-fluorouracil and mitomycin C chemotherapy were selected from an institutional database (n = 106)." | 4.02 | Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. ( Johnsson, A; Nilsson, MP; Scherman, J, 2021) |
| "During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA)." | 3.85 | Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C. ( Aycart, SN; Bhagwandin, S; Feferman, Y; Feingold, D; Kim, J; Labow, DM; Sarpel, U, 2017) |
| "Fifty-six anal cancer patients from 2 institutions received definitive radiation therapy (median primary dose of 54 Gy) using intensity modulated radiation therapy (IMRT, n=49) or 3-dimensional (3D) conformal therapy (n=7) with concurrent 5-fluorouracil (5-FU) and mitomycin C." | 3.85 | Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors. ( Aggarwal, S; Bazan, JG; Chang, DT; Golden, DW; Kopec, M; Lee, AY; Liauw, SL; Pelizzari, CA, 2017) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 3.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)." | 3.67 | Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984) |
| " Fifty-seven patients with postoperative breast cancer received MMF (mitomycin, methotrexate, futraful therapy with SNMC and 60 were given MMF alone." | 3.67 | [Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)]. ( Akimoto, M; Iwasaki, H; Kasai, M; Kimura, M; Matano, S; Nakajima, Y; Sawano, A, 1986) |
| "The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary." | 3.67 | 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986) |
| "In 23 cases of primary advanced breast cancer, intra-arterial infusion chemotherapy of Adriamycin (ADR) and Mitomycin C (MMC), which were injected jointly or individually, was performed and its effects and side effects were studied." | 3.67 | [Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin]. ( Asaishi, K; Ebata, T; Hayasaka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, N; Toda, K; Totsuka, M, 1985) |
| "Mitomycin C together with either vindesine or vinblastine was given to 48 patients with previously treated advanced breast cancer." | 3.66 | Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine. ( Brooks, RJ; Garewal, HS; Jones, SE; Miller, TP, 1983) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| " Our trial failed to demonstrate a significant improvement in response or survival when patients with metastatic NSCLC were treated, in addition to ifosfamide and mitomycin, by combination of moderate dosages of cisplatin and carboplatin instead of moderate dosage of cisplatin alone." | 2.69 | Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. ( Alexopoulos, CG; Baumöhl, J; Berghmans, T; Florin, MC; Klastersky, J; Koumakis, G; Lafitte, JJ; Mommen, P; Ninane, V; Paesmans, M; Schmerber, J; Sculier, JP; Thiriaux, J; Zacharias, C, 2000) |
| "N&V and leukopenia were the major side effects." | 2.68 | Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995) |
| " No serious adverse effects were observed in any of the groups." | 2.66 | [Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan]. ( Abe, O; Hattori, T; Inokuchi, K; Kasai, Y; Kikuchi, K; Komi, N; Kondo, T; Kunii, Y; Ogawa, N; Taguchi, T, 1987) |
| " In total, 28 adverse effects were observed after 30% of the procedures." | 1.38 | Complications and toxicity after abdominal and pelvic hypoxic stop-flow perfusion chemotherapy: incidence and assessment of risk factors. ( Askoxylakis, J; de Bree, E; Melissas, J; Metaxari, M; Michalakis, J; Romanos, J; Tsiftsis, DD; Tsogkas, J; Volakakis, E, 2012) |
| "We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy." | 1.35 | Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. ( Aydogan, B; Chmura, SJ; Devisetty, K; Jani, AB; Kindler, HL; Mell, LK; Miller, RC; Mundt, AJ; Roeske, JC; Salama, JK; Schomas, DA, 2008) |
| "HCT116 human colon cancer cells and T47D human breast cancer cells were incubated with or without dimethyl fumarate or sulforaphane followed by mitomycin C or RH1 treatment, and cytotoxic activity was measured by a clonogenic (HCT116) or MTT assay (T47D)." | 1.33 | Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo. ( Begleiter, A; Digby, T; Leith, MK; Thliveris, JA, 2005) |
| " The developed pharmacokinetic-pharmacodynamic model can be used to simulate different dosage schemes in order to optimise mitomycin administration during HIPEC." | 1.32 | Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. ( Beijnen, JH; Mathôt, RA; Sparidans, RW; van Ruth, S; Verwaal, VJ; Zoetmulder, FA, 2004) |
| "The 36 patients with breast cancer were divided into two groups." | 1.28 | [The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer]. ( Hagiwara, M; Kanasugi, K; Komoriyama, H; Morikubo, M; Oikawa, H; Satoh, T; Tsukikawa, S; Yamaguchi, S, 1990) |
| "This study observed the effect of chemotherapy combined with Chinese herbs and western drugs on white blood cell count in 31 patients with gastric cancer." | 1.28 | [Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients]. ( Chen, JZ, 1990) |
| "Overall median survival was 352 days in colon cancer and 449 days in gastric cancer." | 1.28 | [A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer]. ( Arai, Y; Endo, T; Kido, C; Miyake, Y; Sakamoto, K, 1989) |
| " These results indicate that JTX enhances the anti-tumor activity of MMC and lessens the adverse effects of it." | 1.27 | Protective effects of juzentaihoto, dried decoctum of 10 Chinese herbs mixture, upon the adverse effects of mitomycin C in mice. ( Aburada, M; Hosoya, E; Ito, E; Nakamura, M; Takeda, S, 1983) |
| " These findings suggested that dicoumarol might enhance the toxicity of MC to the hypoxic cells of solid tumors, without increasing the toxic side effects of the antibiotic to the host." | 1.27 | Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. ( Keyes, SR; Rockwell, S; Sartorelli, AC, 1985) |
| "Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea." | 1.27 | The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (45.45) | 18.7374 |
| 1990's | 14 (21.21) | 18.2507 |
| 2000's | 13 (19.70) | 29.6817 |
| 2010's | 7 (10.61) | 24.3611 |
| 2020's | 2 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Sami, SM | 2 |
| Iyengar, BS | 2 |
| Tarnow, SE | 1 |
| Remers, WA | 2 |
| Bradner, WT | 2 |
| Schurig, JE | 2 |
| Nilsson, MP | 1 |
| Johnsson, A | 1 |
| Scherman, J | 1 |
| Feferman, Y | 1 |
| Bhagwandin, S | 1 |
| Kim, J | 1 |
| Aycart, SN | 1 |
| Feingold, D | 1 |
| Labow, DM | 1 |
| Sarpel, U | 1 |
| Bazan, JG | 2 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 1 |
| Kapp, DS | 1 |
| Kidd, EA | 1 |
| Koong, AC | 1 |
| Chang, DT | 2 |
| Hompes, D | 1 |
| D'Hoore, A | 1 |
| Wolthuis, A | 1 |
| Fieuws, S | 1 |
| Mirck, B | 1 |
| Bruin, S | 1 |
| Verwaal, V | 1 |
| Lee, AY | 1 |
| Golden, DW | 1 |
| Kopec, M | 1 |
| Pelizzari, CA | 1 |
| Aggarwal, S | 1 |
| Liauw, SL | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 2 |
| Kripp, M | 2 |
| Lukan, N | 2 |
| Merx, K | 2 |
| Hofmann, WK | 1 |
| Hochhaus, A | 2 |
| Hofheinz, RD | 2 |
| de Bree, E | 1 |
| Romanos, J | 1 |
| Tsogkas, J | 1 |
| Askoxylakis, J | 1 |
| Metaxari, M | 1 |
| Michalakis, J | 1 |
| Volakakis, E | 1 |
| Melissas, J | 1 |
| Tsiftsis, DD | 1 |
| Schippert, C | 1 |
| Warm, M | 1 |
| Blohmer, JU | 1 |
| du Bois, A | 1 |
| Lück, HJ | 1 |
| KUBOTA, J | 1 |
| HIGUCHI, K | 1 |
| UEMATSU, K | 1 |
| KADONO, T | 1 |
| van Ruth, S | 1 |
| Mathôt, RA | 1 |
| Sparidans, RW | 1 |
| Beijnen, JH | 1 |
| Verwaal, VJ | 1 |
| Zoetmulder, FA | 1 |
| Haffty, BG | 1 |
| Wilson, LD | 1 |
| Son, YH | 1 |
| Cho, EI | 1 |
| Papac, RJ | 1 |
| Fischer, DB | 1 |
| Rockwell, S | 2 |
| Sartorelli, AC | 2 |
| Ross, DA | 1 |
| Sasaki, CT | 1 |
| Fischer, JJ | 1 |
| Digby, T | 1 |
| Leith, MK | 1 |
| Thliveris, JA | 1 |
| Begleiter, A | 1 |
| Kemeny, N | 1 |
| Eid, A | 1 |
| Stockman, J | 1 |
| Gonen, M | 1 |
| Schwartz, L | 1 |
| Tetzlaff, E | 1 |
| Paty, P | 1 |
| Sadahiro, S | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takahashi, T | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 2 |
| Long, HJ | 2 |
| Blessing, JA | 1 |
| Sorosky, J | 1 |
| Polyzos, A | 1 |
| Koulentianos, E | 1 |
| Tzianoumis, L | 1 |
| Sfikakis, P | 1 |
| Mell, LK | 1 |
| Schomas, DA | 1 |
| Salama, JK | 1 |
| Devisetty, K | 1 |
| Aydogan, B | 1 |
| Miller, RC | 1 |
| Jani, AB | 1 |
| Kindler, HL | 1 |
| Mundt, AJ | 1 |
| Roeske, JC | 1 |
| Chmura, SJ | 1 |
| Gnad-Vogt, U | 1 |
| Schultheis, B | 1 |
| Kamidono, S | 1 |
| Fujii, A | 1 |
| Hamami, G | 1 |
| Nakano, Y | 1 |
| Umezu, K | 1 |
| Oda, Y | 1 |
| Ishigami, J | 1 |
| Salvati, F | 1 |
| Cruciani, AR | 1 |
| De Marinis, A | 1 |
| Nunziati, F | 1 |
| Portalone, L | 1 |
| Kasajima, T | 1 |
| Yamakawa, M | 1 |
| Maeda, K | 1 |
| Matsuda, M | 1 |
| Dobashi, M | 1 |
| Imai, Y | 1 |
| Garewal, HS | 1 |
| Brooks, RJ | 1 |
| Jones, SE | 1 |
| Miller, TP | 1 |
| Beck, TM | 1 |
| Curtis, PW | 1 |
| Woodard, DA | 1 |
| Hart, NE | 1 |
| Smith, CE | 1 |
| Aburada, M | 1 |
| Takeda, S | 1 |
| Ito, E | 1 |
| Nakamura, M | 1 |
| Hosoya, E | 1 |
| Chahinian, AP | 1 |
| Green, G | 1 |
| Holland, JF | 1 |
| Fornasiero, A | 1 |
| Cartei, G | 2 |
| Daniele, O | 1 |
| Fosser, V | 1 |
| Fiorentino, MV | 1 |
| Pacini, P | 1 |
| Tucci, E | 1 |
| Algeri, R | 1 |
| Rinaldini, M | 1 |
| Guarnieri, A | 1 |
| Valzelli, S | 1 |
| Neri, B | 1 |
| Kohno, N | 1 |
| Ichikawa, G | 1 |
| Shirasaka, T | 1 |
| Inuyama, Y | 1 |
| Kawaida, M | 1 |
| Ohnuma, T | 1 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Aquino, A | 1 |
| Gonnelli, S | 1 |
| Nemoto, K | 1 |
| Ogino, M | 1 |
| Sugawara, Y | 1 |
| Abe, F | 1 |
| Ito, J | 1 |
| Takeuchi, T | 2 |
| Grau, JJ | 1 |
| Estapé, J | 1 |
| Alcobendas, F | 1 |
| Pera, C | 1 |
| Daniels, M | 1 |
| Terés, J | 1 |
| Katakami, N | 1 |
| Hasegawa, T | 1 |
| Umeda, B | 1 |
| Adachi, S | 2 |
| Ishii, N | 1 |
| Takada, Y | 1 |
| Tsubota, N | 1 |
| Nakano, K | 1 |
| Tamura, R | 1 |
| Nakai, H | 1 |
| Iop, A | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| Hartmann, JT | 1 |
| Harstrick, A | 1 |
| Daikeler, T | 1 |
| Kollmannsberger, C | 1 |
| Müller, C | 1 |
| Seeber, S | 1 |
| Kanz, L | 1 |
| Bokemeyer, C | 1 |
| Sculier, JP | 1 |
| Lafitte, JJ | 1 |
| Paesmans, M | 1 |
| Thiriaux, J | 1 |
| Alexopoulos, CG | 1 |
| Baumöhl, J | 1 |
| Schmerber, J | 1 |
| Koumakis, G | 1 |
| Florin, MC | 1 |
| Zacharias, C | 1 |
| Berghmans, T | 1 |
| Mommen, P | 1 |
| Ninane, V | 1 |
| Klastersky, J | 1 |
| Kornek, GV | 1 |
| Pötter, R | 1 |
| Selzer, E | 1 |
| Schratter, A | 1 |
| Ulrich-Pur, H | 1 |
| Rogy, M | 1 |
| Kraus, G | 1 |
| Scheithauer, W | 1 |
| Yoshimoto, M | 1 |
| Saito, M | 1 |
| Tada, T | 1 |
| Kasumi, KT | 1 |
| Valentini, V | 1 |
| Coco, C | 1 |
| Cellini, N | 1 |
| Picciocchi, A | 1 |
| Fares, MC | 1 |
| Rosetto, ME | 1 |
| Mantini, G | 1 |
| Morganti, AG | 1 |
| Barbaro, B | 1 |
| Cogliandolo, S | 1 |
| Nuzzo, G | 1 |
| Tedesco, M | 1 |
| Ambesi-Impiombato, F | 1 |
| Cosimelli, M | 1 |
| Rotman, M | 1 |
| Edmonson, JH | 1 |
| Petersen, IA | 1 |
| Shives, TC | 1 |
| Mahoney, MR | 1 |
| Rock, MG | 1 |
| Haddock, MG | 1 |
| Sim, FH | 1 |
| Maples, WJ | 1 |
| O'Connor, MI | 1 |
| Gunderson, LL | 1 |
| Foo, ML | 1 |
| Pritchard, DJ | 1 |
| Buckner, JC | 1 |
| Stafford, SL | 1 |
| Laurie, JA | 1 |
| Hahn, RG | 1 |
| Therneau, TM | 1 |
| Patel, SR | 1 |
| Mailliard, JA | 2 |
| Windschitl, HE | 1 |
| Twito, DI | 1 |
| Morton, RF | 1 |
| Krook, JE | 3 |
| Tsukikawa, S | 1 |
| Oikawa, H | 1 |
| Satoh, T | 1 |
| Morikubo, M | 1 |
| Komoriyama, H | 1 |
| Hagiwara, M | 1 |
| Kanasugi, K | 1 |
| Yamaguchi, S | 1 |
| Talebian, A | 1 |
| Green, D | 1 |
| Hammer, CF | 1 |
| McPherson, E | 1 |
| Schein, PS | 2 |
| Hayashi, Y | 1 |
| Kato, M | 1 |
| Matsuura, T | 1 |
| Yamada, Y | 1 |
| Ito, G | 1 |
| Yamamoto, K | 1 |
| Cullinan, S | 1 |
| Moertel, CG | 1 |
| Wieand, HS | 1 |
| Schutt, AJ | 1 |
| Foley, JF | 2 |
| Norris, BD | 1 |
| Kardinal, CG | 1 |
| Tschetter, LK | 1 |
| Barlow, JF | 1 |
| Chen, JZ | 1 |
| Inoue, Y | 1 |
| Sawada, T | 1 |
| Shimizu, T | 1 |
| Ishiguro, M | 1 |
| Wakatsuki, T | 1 |
| Hamazoe, R | 1 |
| Shimizu, N | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Shimizu, E | 1 |
| Kamei, T | 1 |
| Kimura, K | 1 |
| Mukai, J | 1 |
| Nakamura, Y | 1 |
| Kunishige, E | 1 |
| Fukuta, K | 1 |
| Tani, K | 1 |
| Sone, S | 1 |
| Ogura, T | 1 |
| Keyes, SR | 1 |
| Ingle, JN | 1 |
| Schaid, DJ | 1 |
| Gerstner, JB | 1 |
| Pfeifle, DM | 1 |
| Marschke, RF | 1 |
| McCormack, GW | 1 |
| Arai, Y | 1 |
| Endo, T | 1 |
| Miyake, Y | 1 |
| Sakamoto, K | 1 |
| Kido, C | 1 |
| Giaccone, G | 1 |
| Bagatella, M | 1 |
| Donadio, M | 1 |
| Bonardi, GM | 1 |
| Testore, F | 1 |
| Ferrati, P | 1 |
| Ciuffreda, L | 1 |
| Calciati, A | 1 |
| Toda, K | 1 |
| Asaishi, K | 1 |
| Okazaki, A | 1 |
| Okazaki, Y | 1 |
| Okazaki, M | 1 |
| Ebata, T | 1 |
| Totsuka, M | 1 |
| Hayasaka, H | 1 |
| Sato, N | 1 |
| Narimatsu, E | 1 |
| Di Costanzo, F | 1 |
| Gori, S | 1 |
| Tonato, M | 1 |
| Buzzi, F | 1 |
| Crino, L | 1 |
| Grignani, F | 1 |
| Davis, S | 1 |
| Vaughn, CB | 1 |
| Chapman, J | 1 |
| Garland, M | 1 |
| Pederson, B | 1 |
| Demitrish, MM | 1 |
| Chinn, B | 1 |
| Ward, D | 1 |
| Enochs, K | 1 |
| Groshko, G | 1 |
| Rocchio, R | 1 |
| Akimoto, M | 1 |
| Kimura, M | 1 |
| Sawano, A | 1 |
| Iwasaki, H | 1 |
| Nakajima, Y | 1 |
| Matano, S | 1 |
| Kasai, M | 1 |
| Kunii, Y | 1 |
| Kikuchi, K | 1 |
| Kasai, Y | 1 |
| Abe, O | 1 |
| Kondo, T | 1 |
| Taguchi, T | 1 |
| Hattori, T | 1 |
| Inokuchi, K | 1 |
| Komi, N | 1 |
| Hattori, H | 1 |
| Mikuriya, S | 1 |
| Mamiya, T | 1 |
| Hatano, K | 1 |
| Shiina, T | 1 |
| Yamada, T | 1 |
| Takada, M | 1 |
| Fukuoka, M | 1 |
| Takifuji, N | 1 |
| Sakai, N | 1 |
| Ryu, S | 1 |
| Masuda, N | 1 |
| Matsui, K | 1 |
| Negoro, S | 1 |
| Kusunoki, Y | 1 |
| Tsubura, E | 1 |
| van der Gaast, A | 1 |
| Verweij, J | 1 |
| Planting, AS | 1 |
| Stoter, G | 1 |
| Goldberg, RM | 1 |
| Smith, FP | 1 |
| Ueno, W | 1 |
| Ahlgren, JD | 1 |
| Perren, TJ | 1 |
| Blackledge, G | 1 |
| Mould, JJ | 1 |
| Chetiyawardana, AD | 1 |
| Morrison, M | 1 |
| Hancock, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C[NCT05513183] | 74 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus[NCT00033644] | Phase 2 | 0 participants | Interventional | 2002-03-31 | Terminated | ||
| A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitomycin and Leukopenia
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
25 trials available for mitomycin and Leukopenia
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Mitomycin C in combination with vinorelbine in anthracycline- and/or taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.
Topics: Analysis of Variance; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Thera | 2005 |
Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Dose- | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Doxorubicin; Dr | 2005 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administ | 1994 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Leukopenia; Liver Ne | 1993 |
[Effect of timing of granulocyte-colony stimulating factor administration on leukopenia induced by systemic chemotherapy in patients with non-small-cell lung cancer--multi-center randomized crossover study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Ove | 1996 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-S | 2000 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo | 2001 |
Unexpected increase in the bone marrow toxicity of mitomycin C (MMC).
Topics: Antibiotics, Antineoplastic; Bone Marrow; Female; Humans; Leukopenia; Mitomycin; Thrombocytopenia | 2001 |
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined | 2002 |
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Topics: Acid Phosphatase; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Doxorubicin; Fluo | 1992 |
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto | 1990 |
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap | 1989 |
Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; | 1989 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorourac | 1987 |
[Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method].
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combin | 1988 |
41 other studies available for mitomycin and Leukopenia
| Article | Year |
|---|---|
Mitomycin C analogues with aryl substituents on the 7-amino group.
Topics: Animals; Antibiotics, Antineoplastic; Indicators and Reagents; Leukemia P388; Leukopenia; Magnetic R | 1984 |
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
Topics: Animals; Ethylamines; Female; Leukemia L1210; Leukemia P388; Leukopenia; Melanoma; Mice; Mitomycins; | 1983 |
Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2021 |
Conflicting Data on the Incidence of Leukopenia and Neutropenia After Heated Intraperitoneal Chemotherapy with Mitomycin C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Che | 2017 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Blood Loss, Surgical; Chemotherapy, Ca | 2014 |
Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; | 2017 |
Complications and toxicity after abdominal and pelvic hypoxic stop-flow perfusion chemotherapy: incidence and assessment of risk factors.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
[TREATMENTS OF LEUKOPENIA ASSOCIATED WITH THE THERAPY OF MALIGNANT TUMORS].
Topics: Anemia; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Transplantation; Japan; Leukocyte Count | 1963 |
THERAPEUTIC EFFECT OF ANTICANCER DRUGS ON SKIN CANCER.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Carcinoma, Basal Cell; Carcinoma, Squamous | 1963 |
[STUDIES ON THE EFFECTS OF MITOMYCIN C AGAINST PATIENTS WITH MALIGNANT TUMORS, PARTICULARLY ON THE CHANGES OF SERUM IRON, SERUM COPPER AND IRON BINDING CAPACITY. I. EFFECTS OF MITOMYCIN C AGAINST NORMAL DOGS].
Topics: Agranulocytosis; Anemia; Animals; Blood Chemical Analysis; Blood Platelets; Blood Protein Electropho | 1964 |
Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
Topics: Antibiotics, Antineoplastic; Area Under Curve; Bayes Theorem; Colorectal Neoplasms; Female; Humans; | 2004 |
Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Aziridines; Benzoquinones; Cell Line, Tumor; Cell Survival; Dose-Res | 2005 |
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; H | 1989 |
Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplas | 2008 |
New preoperative chemotherapy for bladder cancer using combination hemodialysis and direct hemoperfusion: preliminary report.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Bleomycin; Combined Modality Therapy; Dogs; Doxorubicin | 1984 |
Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Br | 1984 |
[Effect of cepharanthin on peripheral leukocytopenia caused by antineoplastic agents].
Topics: Alkaloids; Animals; Benzylisoquinolines; Fluorouracil; Leukopenia; Lymphoma; Mice; Mice, Inbred Stra | 1983 |
Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Fema | 1983 |
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1984 |
Protective effects of juzentaihoto, dried decoctum of 10 Chinese herbs mixture, upon the adverse effects of mitomycin C in mice.
Topics: Animals; Body Weight; Drug Interactions; Drugs, Chinese Herbal; Leukemia P388; Leukopenia; Male; Mic | 1983 |
FAM2 regimen in disseminated gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1984 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
Improvement of mitomycin C- and cyclophosphamide-induced thrombocytopenia and leucocytopenia by prior treatment with deoxyspergualin in dogs.
Topics: Animals; Cyclophosphamide; Dogs; Guanidines; Immunosuppressive Agents; Leukocyte Count; Leukopenia; | 1994 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
[The effect of cepharanthin on adjuvant chemotherapy induced bone marrow suppression in patients with breast cancer].
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Bone Marrow; Breast | 1990 |
New sugar mitomycin C analogues: preparation, murine P388 antitumor activity, and leukopenia induction.
Topics: Animals; Antineoplastic Agents; Leukemia P388; Leukopenia; Magnetic Resonance Spectroscopy; Mitomyci | 1990 |
[Combination chemotherapy including cisplatinum, vindesine and mitomycin C for non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1990 |
[Clinical effect of chemotherapy combined with Chinese herbs and western drugs on leukocytes of gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drugs, Chinese Herbal; Fema | 1990 |
[Pilot combination phase II study of mitomycin C plus cisplatin for non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1989 |
Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.
Topics: Anaerobiosis; Animals; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Combined Modality Ther | 1985 |
[A 5-FU, ADR, MMC combined hepatic arterial infusion therapy in non-resectable liver metastases from colon and gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Flu | 1989 |
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1987 |
[Intra-arterial infusion chemotherapy with anticancer agents for advanced breast cancer--effect and toxicity of mitomycin C and adriamycin].
Topics: Alopecia; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Female; Human | 1985 |
Vindesine and mitomycin C in chemotherapy: refractory advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leuko | 1986 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
[Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Glycyrrhetini | 1986 |
[Effect of intra-thoracic administration of an immune modulator (OK-432) with anti-cancer drugs (ADR and MMC)].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; D | 1988 |
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1988 |
5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu | 1986 |
Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1985 |